Gould Asset Management »

Iovance Biotherapeutics shares owned by Gould Asset Management

Quarter-by-quarter ownership of Iovance Biotherapeutics (IOVA) shares owned by Gould Asset Management from 13F filings

Historical chart of Gould Asset Management investment in Iovance Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Iovance Biotherapeutics held by Gould Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Iovance Biotherapeutics by Gould Asset Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $111k 32k 3.51
2025-12-31 $87k 32k 2.73
2025-09-30 $26k 12k 2.17
2025-06-30 $20k 12k 1.72
2025-03-31 $39k 12k 3.33

More positions owned by Gould Asset Management

S&p 500 Depository Receipt Tr Unit (SPY)
Ishares 0-5 Year Tips Bond Et 0-5 Yr Tips Etf (STIP)
Vanguard Short Term Treasury Short Term Treas (VGSH)
Ishares Barclays 20 Year Tre 20 Yr Tr Bd Etf (TLT)
Vanguard Short-term Corporate Shrt Trm Corp Bd (VCSH)
Invesco Taxable Municipal Bon Taxable Mun Bd (BAB)
Spdr Barclays Intl Treasury B Bloomberg Intl T (BWX)
Vanguard Reit Index Etf Real Estate Etf (VNQ)
Ishares S&p 500 Index Etf Core S&p500 Etf (IVV)
Pimcototal Return Etf Active Bd Etf (BOND)
Vanguard Ftse Developed Marke Van Ftse Dev Mkt (VEA)
Apple (AAPL)
Vanguard Total International Total Int Bd Etf (BNDX)
Wisdomtree Emmkts Ex-stt-ownd Em Ex St-owned (XSOE)
Spdr S&p 500 Fossil Fuel Rese State Street Spd (SPYX)

View all positions for Gould Asset Management

Top funds holding Iovance Biotherapeutics

BlackRock
MHR Fund Management
Vanguard Group
State Street Corporation
Vanguard Capital Management
Two Sigma Investments
Vanguard Portfolio Management
Millennium Management
Goldman Sachs Group
Geode Capital Management
Invenomic Capital Management
Bank of America Corporation
D. E. Shaw & Co
Susquehanna International
Palo Alto Investors

View all funds holding Iovance Biotherapeutics